C

Can Fite Biopharma Ltd
TASE:CANF

Watchlist Manager
Can Fite Biopharma Ltd
TASE:CANF
Watchlist
Price: 1 ILS Market Closed
Market Cap: 78.6m ILS

Can Fite Biopharma Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Can Fite Biopharma Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
C
Can Fite Biopharma Ltd
TASE:CANF
Cash from Operating Activities
-$7.6m
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
0%
Kamada Ltd
NASDAQ:KMDA
Cash from Operating Activities
$28.3m
CAGR 3-Years
19%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Cash from Operating Activities
-$137.7m
CAGR 3-Years
-17%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Cash from Operating Activities
-$7m
CAGR 3-Years
19%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Cash from Operating Activities
-$19.6m
CAGR 3-Years
18%
CAGR 5-Years
5%
CAGR 10-Years
1%
M
Matricelf Ltd
TASE:MTLF
Cash from Operating Activities
-₪11.8m
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Can Fite Biopharma Ltd
Glance View

Market Cap
78.6m ILS
Industry
Biotechnology

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

CANF Intrinsic Value
3.05 ILS
Undervaluation 67%
Intrinsic Value
Price
C

See Also

What is Can Fite Biopharma Ltd's Cash from Operating Activities?
Cash from Operating Activities
-7.6m USD

Based on the financial report for Dec 31, 2024, Can Fite Biopharma Ltd's Cash from Operating Activities amounts to -7.6m USD.

What is Can Fite Biopharma Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
0%

Over the last year, the Cash from Operating Activities growth was 10%. The average annual Cash from Operating Activities growth rates for Can Fite Biopharma Ltd have been 8% over the past three years , 7% over the past five years .

Back to Top